MXPA05005996A - Variantes de butirilcolinesterasa que modifican la actividad de agentes quimioterapeuticos. - Google Patents

Variantes de butirilcolinesterasa que modifican la actividad de agentes quimioterapeuticos.

Info

Publication number
MXPA05005996A
MXPA05005996A MXPA05005996A MXPA05005996A MXPA05005996A MX PA05005996 A MXPA05005996 A MX PA05005996A MX PA05005996 A MXPA05005996 A MX PA05005996A MX PA05005996 A MXPA05005996 A MX PA05005996A MX PA05005996 A MXPA05005996 A MX PA05005996A
Authority
MX
Mexico
Prior art keywords
alter
activity
butyrylcholinesterase
chemotherapeutic agents
butyrylcholinesterase variants
Prior art date
Application number
MXPA05005996A
Other languages
English (en)
Spanish (es)
Inventor
James D Pancook
Original Assignee
Applied Molecular Evolution
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution filed Critical Applied Molecular Evolution
Publication of MXPA05005996A publication Critical patent/MXPA05005996A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA05005996A 2002-12-04 2003-12-04 Variantes de butirilcolinesterasa que modifican la actividad de agentes quimioterapeuticos. MXPA05005996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31066602A 2002-12-04 2002-12-04
PCT/US2003/038684 WO2004050041A2 (en) 2002-12-04 2003-12-04 Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA05005996A true MXPA05005996A (es) 2006-04-18

Family

ID=32468084

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005996A MXPA05005996A (es) 2002-12-04 2003-12-04 Variantes de butirilcolinesterasa que modifican la actividad de agentes quimioterapeuticos.

Country Status (9)

Country Link
US (1) US20080213281A1 (cg-RX-API-DMAC7.html)
EP (1) EP1581253A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006508665A (cg-RX-API-DMAC7.html)
CN (1) CN100341568C (cg-RX-API-DMAC7.html)
AU (1) AU2003298920A1 (cg-RX-API-DMAC7.html)
BR (1) BR0316865A (cg-RX-API-DMAC7.html)
CA (1) CA2507626A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05005996A (cg-RX-API-DMAC7.html)
WO (1) WO2004050041A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP2049661A4 (en) * 2006-08-04 2012-07-04 Pharmathene Inc RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
WO2009139905A2 (en) * 2008-05-16 2009-11-19 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
CA2784861A1 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
CN103898101B (zh) * 2012-12-27 2017-08-08 上海桀蒙生物技术有限公司 利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法
CN104630177A (zh) * 2013-11-08 2015-05-20 中国农业大学 一种利用人丁酰胆碱酯酶迷你基因在乳腺中表达重组人丁酰胆碱脂酶的方法
EP3719123A1 (en) 2014-04-29 2020-10-07 Mayo Foundation for Medical Education and Research Uses of butyrylcholinesterase variants having an enhanced ability to hydrolyze acyl-ghrelin
WO2018053216A1 (en) * 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1008049A1 (en) * 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5506125A (en) * 1993-12-22 1996-04-09 Agracetus, Inc. Gene delivery instrument with replaceable cartridges
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
ATE317452T1 (de) * 1998-06-16 2006-02-15 Nova Molecular Inc Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
CN1331339A (zh) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸
AU2002248256B2 (en) * 2000-12-26 2006-09-28 Applied Molecular Evolution, Inc. Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
US20030153062A1 (en) * 2001-12-20 2003-08-14 Watkins Jeffry D. Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7070973B2 (en) * 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
US7049121B2 (en) * 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use

Also Published As

Publication number Publication date
US20080213281A1 (en) 2008-09-04
CA2507626A1 (en) 2004-06-17
CN1720063A (zh) 2006-01-11
CN100341568C (zh) 2007-10-10
AU2003298920A1 (en) 2004-06-23
JP2006508665A (ja) 2006-03-16
WO2004050041A2 (en) 2004-06-17
EP1581253A2 (en) 2005-10-05
EP1581253A4 (en) 2007-02-14
WO2004050041A3 (en) 2004-10-28
BR0316865A (pt) 2005-10-25

Similar Documents

Publication Publication Date Title
TW200510397A (en) Conjugated complement cascade inhibitors
TW200510927A (en) Stimulus-sensitive composition, compound and pattern formation method using the stimulation-sensitive composition
BG105967A (en) C(7) ester substituted taxanes and their use as antitumor agents
WO2005055932A3 (en) Therapeutic combinations and methods including irm compounds
AU2003225295A1 (en) Substituted pyrroline kinase inhibitors
EP1481077A4 (en) MITOTIC KINESINE HEMMER
IL165624A0 (en) Mitotic kinesin inhibitors
EP1551812A4 (en) MITOTIC KINESINE HEMMER
WO2004058700A3 (en) Mitotic kinesin inhibitors
DE60323749D1 (de) Substituierte pyrroline als kinase inhibitoren
AU2002360488A8 (en) Methods and devices for detection and therapy of atheromatous plaque
SI1485360T1 (sl) Blokatorji natrijevih kanalov
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
WO2005053609A3 (en) Methods of nad+-dependent deacetylase inhibitors
AU2003285934A8 (en) Analogs and prodrugs of buprenorphine
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
WO2004050041A3 (en) Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
DE60019121D1 (de) Kaliumkanäleöffner
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
TW200507840A (en) Method of treating multiple myeloma
TW200508233A (en) Chk-1 inhibitors
EP1435941B8 (en) Wortmannin analogs and methods of using same
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal